Hematology/Oncology

Top Story

VIDEO: Pembrolizumab represents ‘important option’ for metastatic urothelial cancer

June 25, 2017

CHICAGO — Improvements in response duration and side effect profile seen in the KEYNOTE-045 trial of pembrolizumab establish this therapy “as a standard of care” for patients with previously treated, metastatic urothelial cancer, according to Matthew Galsky, MD, professor of medicine (hematology and medical oncology) and urology at the Icahn School of Medicine at Mount Sinai Hospital in New York.

The Wistar Institute appoints associate professor

June 25, 2017
The Wistar Institute appointed Daniel W. Kulp, PhD, as associate professor in its vaccine center and translational tumor immunology program. Kulp’s research…

University of Alabama at Birmingham appoints cancer center director

June 24, 2017
Michael J. Birrer, MD, PhD, has been named director of University of Alabama at Birmingham Comprehensive Cancer Center. Birrer’s appointment will be effective Aug…
Meeting NewsVideo

VIDEO: Questions remain regarding use of gene-targeted therapy for lung cancer

June 23, 2017
CHICAGO — Suresh S. Ramalingam, MD, deputy director of Winship Cancer Institute of Emory University, discusses the results of a phase 3 trial that demonstrated…

10 updates in immunotherapy research

June 23, 2017
In recognition of Cancer Immunotherapy Month, Cancer Research Institute has organized a series of educational and social events designed to raise awareness regarding…
More News Headlines »
CME

Immune Checkpoint Inhibitors for Advanced Melanoma: Clinical Updates and Multidisciplinary Strategies

This activity is supported by an educational grant from Bristol-Myers Squibb.

Incidence rates of melanoma in the United States continue to rise, with an estimated 87,110 new cases being diagnosed…
More »
Video
Meeting News

VIDEO: Results of LATITUDE trial reinforce long-hypothesized theory in prostate cancer treatment

June 21, 2017
More »
Featured
ASCO Annual Meeting

ASCO Annual Meeting

CME

Toward Precision Medicine for Advanced Melanoma Management: Making the Most of Targeted Agents

This activity is supported by an educational grant from Novartis.

The identification and utilization of melanoma specific biomarkers continues to be of importance for diagnosis and…
More »
Current Issues
View the Current Issue
HemOnc Today
Advertisement
Advertisement